Drug intelligence / Profile preview

methotrexate + mitomycin C

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Intravenous

Overview

Methotrexate (MTX) and mitomycin C (MMC) is a combination chemotherapy regimen used primarily in the treatment of metastatic breast cancer and non-small cell lung cancer. This combination has shown efficacy in patients with human epidermal growth factor receptor type 2 (HER2)-negative metastatic breast cancer who have been previously treated with multiple regimens including anthracycline, taxane, capecitabine, and vinorelbine. The combination has demonstrated effectiveness even in cases resistant to newer drugs such as eribulin and bevacizumab with paclitaxel.

Other names: MMC/MTX

Targets

DHFR (Dihydrofolate reductase)DNAATIC (Aminoimidazole carboxamide ribonucleotide transformylase)TS (Thymidylate synthase)

Beyond the preview

Go deeper on methotrexate + mitomycin C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on methotrexate + mitomycin C.

Explore the full profile